These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35763306)

  • 1.
    Crémet L; Joffraud L; Eschapasse E; Bihouée T; Tissot A; Gibaud S; Persyn E
    Microb Drug Resist; 2022 Aug; 28(8):877-881. PubMed ID: 35763306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Looking for
    Ranieri EM; Denicolò S; Stolfa S; Dalfino L; Bavaro DF; Saracino A; Ronga L; Del Prete R; Mosca A
    J Chemother; 2023 Nov; 35(7):610-613. PubMed ID: 37615040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone.
    Moriceau C; Eveillard M; Lemarié C; Chenouard R; Pailhoriès H; Kempf M
    Med Mal Infect; 2020 May; 50(3):305-307. PubMed ID: 32014291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
    Biagi M; Lamm D; Meyer K; Vialichka A; Jurkovic M; Patel S; Mendes RE; Bulman ZP; Wenzler E
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis.
    De Almeida Torres N; Morales Junior R; Bueno Lopes LF; Zeigler R; Everson Uip D
    J Infect Dev Ctries; 2023 Jun; 17(6):881-885. PubMed ID: 37406060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
    Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
    Avery LM; Nicolau DP
    Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex.
    Li W; Zhang J; Fu Y; Wang J; Liu L; Long W; Yu K; Li X; Wei C; Liang X; Wang J; Li C; Zhang X
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1309-1318. PubMed ID: 38700663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
    Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
    [No Abstract]   [Full Text] [Related]  

  • 15. Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test.
    Harris H; Tao L; Jacobs EB; Bergman Y; Adebayo A; Tekle T; Lewis S; Dahlquist A; Abbey TC; Wenzler E; Humphries R; Simner PJ
    J Clin Microbiol; 2023 May; 61(5):e0164722. PubMed ID: 37070979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales.
    Romina PE; Lucía A; Leticia C; Federica F; Pablo Á; Verónica S; Antonio G; Inés B; Rafael V
    J Glob Antimicrob Resist; 2023 Dec; 35():62-66. PubMed ID: 37611893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of aztreonam/ceftazidime-avibactam synergism and proposal of a new methodology for the evaluation of susceptibility in vitro.
    Collar GDS; Moreira NK; Becker J; Barth AL; Caierão J
    Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116236. PubMed ID: 38537506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yu W; Xiong L; Luo Q; Chen Y; Ji J; Ying C; Liu Z; Xiao Y
    Front Cell Infect Microbiol; 2021; 11():780365. PubMed ID: 34900759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.